Mapp Biopharmaceutical, U.S. Department of Health and Human Services infectious news

HHS's Biomedical Advanced Research and Development Authority (BARDA) awarded Mapp a $24.9 million, 18-month contract to develop ZMapp Ebola treatment. BARDA has the option to extend the contract up to a total of $42.3 million. Under the contract, Mapp will manufacture a small amount of ZMapp for preclinical studies and early stage clinical safety trials and will work with BARDA on optimizing and scaling the manufacturing process. Mapp could not be reached for comment. ZMapp combines components of mAbs targeting Ebola glycoproteins GP1 and GP2. Mapp licensed two of the mAbs from Defyrus Inc. (Toronto, Ontario). ...